Cisplatin, cytosine arabinoside, and pentoxifylline in the treatment of squamous cell carcinoma of the head and neck
| Autor: | David J. Stewart, Andre Lamothe, M. Christine Cripps, Howard Fingert, Jean Gerin-Lajoie, Guy Laframboise |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment Gastroenterology Drug Administration Schedule Pentoxifylline Oral administration Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Cisplatin Chemotherapy business.industry Head and neck cancer Remission Induction Cytarabine Middle Aged medicine.disease Surgery Oncology Head and Neck Neoplasms Toxicity Carcinoma Squamous Cell Female medicine.symptom business medicine.drug |
| Zdroj: | American journal of clinical oncology. 16(2) |
| ISSN: | 0277-3732 |
| Popis: | Nine patients were entered on a Phase I-II study of cisplatin, cytosine arabinoside, and pentoxifylline in the treatment of advanced head and neck cancer. The treatment regimen consisted of cisplatin 100 mg/m2 intravenously on day 1 only, cytosine arabinoside 2,000 mg/m2 intravenously on days 1 and 2, and pentoxifylline 400 mg orally three times daily beginning 7 to 14 days before the chemotherapy. The pentoxifylline was continued between chemotherapy cycles. Chemotherapy courses were repeated at 3- to 4-week intervals. Partial remission were seen in two patients, two patients were stable, and five patients failed on treatment. Dose-limiting toxicity was granulocytopenia. Pentoxifylline itself caused some nausea and anorexia. Although the patient numbers were small, there was no indication that pentoxifylline increased the efficacy of this chemotherapy in head and neck cancer. It is possible that another dose schedule might have been more effective. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|